YAP Mediates EGFR Inhibitor-Induced Dormancy in EGFR-Mutant Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Epidermal growth factor receptor (EGFR) mutations drive many cancers.
• Targeted therapies inhibiting EGFR and MEK pathways are standard treatments.
• Resistance to these therapies remains a significant clinical challenge.

Purpose of the Study:

• To investigate the mechanisms underlying resistance to EGFR and MEK inhibitors in EGFR-mutant cancer cells.
• To identify key molecular players involved in mediating treatment resistance.

Main Methods:

• Utilized cell culture models of EGFR-mutant cancer.
• Employed genetic and pharmacological approaches to modulate YAP activity.
• Assessed cell viability and pathway signaling in response to targeted inhibitors and YAP modulation.

Main Results:

• YAP activation was identified as a critical mediator of resistance to both EGFR and MEK inhibition.
• Inhibition of YAP sensitized resistant cells to targeted therapies.
• EGFR-mutant cancer cells with YAP activation exhibited reduced sensitivity to standard treatments.

Conclusions:

• YAP activation confers resistance to EGFR and MEK inhibitors in EGFR-mutant cancers.
• Targeting YAP in combination with existing therapies may represent a viable strategy to overcome treatment resistance.
• Further research into YAP-mediated resistance mechanisms is warranted for clinical application.